Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech (Hong Kong) Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam.
The Group’s stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia are accredited by AABB (formerly known as the American Association of Blood Banks).
In 2019, the Group has successfully performed 14 cord blood and 1 cord tissue releases to support medical treatment carried out at 6 healthcare institutions in 6 countries.
Traded as: SGX: P8A
Industry: Healthcare Services
Founded: 2 May 2001; 19 years ago
Headquarters: Singapore
Products: Cord blood banking, cord lining banking, metabolic screening and other products catering to the mother & child segment
Website: www.cordlife.com